New Research Shows Significant Benefits for COPD Patients in the Home Using Fisher Paykel Healthcare#s myAirvo

Food and Healthcare Press Releases Friday April 20, 2018 15:35
AUCKLAND, New Zealand--20 Apr--PRNewswire/InfoQuest

Fisher & Paykel Healthcare Corporation Limited announced today that new research has been published in the International Journal of COPD which demonstrates significant benefits of nasal high flow therapy for COPD* patients using Fisher & Paykel Healthcare's myAirvo device.

The study[1], a randomised controlled trial undertaken in Denmark, investigated the long-term effects of nasal high flow therapy for COPD patients already being treated with long-term oxygen therapy.

The trial showed statistically significant results, with the primary outcome being a significant reduction in patients' exacerbation rate, or worsening of their condition (from 4.95 to 3.12 per patient per year, p is less than 0.001) for those being treated with nasal high flow therapy.

The study also showed for those patients using the myAirvo, that all cause hospitalisation rates decreased from a rate of 1.39 to 0.79 per patient, over the course of the year, for those who followed the protocol. Other positive results included the treatment group (myAirvo) being better than the control group (standard care) in several quality of life assessments, less breathlessness, better mobility and lower carbon dioxide retention levels for these chronic patients.

The trial is the largest study of this treatment length to have been conducted in a home environment and was led by researchers Line Storgaard and Dr Ulla Weinreich. It followed 200 patients with COPD on long-term oxygen for 16 hours or more per day over a period of one year.

Vice President - Products & Technology at Fisher & Paykel Healthcare, Andrew Somervell said, "It is positive to see such convincing outcomes for patients with COPD. We expect this study to increase clinical interest in the myAirvo home respiratory device and encourage clinical change and adoption around the world."

This study adds to other positive results that were recently published in the Annals of the American Thoracic Society. Led by Dr Kazuma Nagata of Kobe City Medical Centre General Hospital, this study was a multi-centre trial in Japan with cross-over design, studying stable COPD patients with hypercapnia[2]. This research also demonstrated a clinically significant improvement in quality of life for patients (the mean total score improved by 7.8 points, p is less than 0.01), and a decrease in hypercapnia levels for patients with stable hypercapnic COPD.

As a result of the positive outcomes of this pilot trial, a larger multi-centre trial has commenced.
Together, these new studies add to the growing body of evidence showing the efficacy of nasal high flow therapy in the home for COPD patients using the myAirvo device.
*Chronic Obstructive Pulmonary Disease

[1] Storgaard L, Hockey H, Laursen B, Weinreich U. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis. 2018;13:1195-1205. Fisher & Paykel Healthcare provided the myAirvo devices and contributed to the funding of this study.

[2] Nagata K, Kikuchi T, Horie T, Shiraki A, Kitajima T, Kadowaki T et al. Domiciliary High-Flow Nasal Cannula Oxygen Therapy for Patients with Stable Hypercapnic Chronic Obstructive Pulmonary Disease. A Multicenter Randomized Crossover Trial. Ann Am Thorac Soc. 2018;15(4):432-439.


Latest Press Release

Most Thai consumers want to improve their diets and are open to healthier product reformulation

According to a new report by Food Industry Asia (FIA) and research firm IGD, almost all consumers in Thailand (99 per cent) are interested in improving their diets and a majority (82 per cent) are happy for products to be reformulated, provided that...

Kemin Launches New Vision and Logo for the Future

Global ingredient manufacturer sets sights on sustainably transforming 80 percent of the world by 2042 Today Kemin Industries, a global ingredient manufacturer, unveiled its new global vision and logo to align the company strategically for 2042 and...

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The...

Zeus Expands Portfolio with New Polyimide Family of Products

Products Include PI Tubing, PI Coated Wire, PI Glide(TM) Tubing, and PI Glide(TM) Coated Wire Zeus Industrial Products, Inc. (Zeus), a leading polymer solutions provider and material science innovator, has announced the introduction of a new polyimide...

SCG partners up with Frances Institut Pasteur to combat dengue with innovations to reduce mosquito breeding

Dr. Suracha Udomsak, Chief Technology Officer, on behalf of Chemicals Business, SCG, and Dr. Anavaj Sakuntabhai, Coordinator of the Defeat Dengue Program, Head of Structure, Functional Genetics of Infectious Diseases, representing Institut Pasteur,...

Related Topics